Cayman Fludarabine Phosphate

Fludarabine phosphate is a prodrug form of fludarabine (Item No. 14128) and 2-fluoro-ara-ATP.¹ It is dephosphorylated in vivo to fludarabine and re-phosphorylated intracellularly to the active form, 2-fluoro-ara-ATP, which inhibits DNA synthesis.^2,3 Fludarabine phosphate reduces viability of, and induces apoptosis in, N-Myc-overexpressing LASCPC-01 neuroendocrine prostate cancer cells (IC₅₀ = 17.67 µM).¹ It also reduces N-Myc protein levels when used at a concentration of 25 µM for at least 48 hours but does not reduce the levels of N-Myc mRNA. Fludarabine phosphate (120 mg/kg per day) reduces tumor volume in N-Myc-overexpressing 22Rv1-N-Myc and LASCPC-01, but not non-N-Myc-overexpressing 22Rv1, mouse xenograft models. Fludarabine phosphate is also an inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA-dependent RNA polymerase (RdRp; EC₅₀ = 0.93 µM).⁴ Formulations containing fludarabine phosphate have been used in the treatment of B cell chronic lymphocytic leukemia (CLL).

WARNING This product is not for human or veterinary use.